Bcal Diagnostics Ltd

AU:BDX Australia Diagnostics & Research
Market Cap
$21.46 Million
AU$34.66 Million AUD
Market Cap Rank
#28379 Global
#732 in Australia
Share Price
AU$0.09
Change (1 day)
-6.00%
52-Week Range
AU$0.05 - AU$0.14
All Time High
AU$0.25
About

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated… Read more

Bcal Diagnostics Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.00%

Bcal Diagnostics Ltd (BDX) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
AU$0.00
Cash + Short-term Investments
Total Assets
AU$8.37 Million
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2022)

This chart shows how Bcal Diagnostics Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Bcal Diagnostics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Bcal Diagnostics Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Bcal Diagnostics Ltd Industry Peers by Asset Resilience Ratio

Compare Bcal Diagnostics Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ADCNF
OTCGREY:ADCNF
Diagnostics & Research 1.12%
Berry Genomics Co Ltd
SHE:000710
Diagnostics & Research 0.45%
NSN Co. Ltd
KQ:031860
Diagnostics & Research 1.72%
JOONGANG DNM Co.Ltd
KQ:051980
Diagnostics & Research 27.26%
GeneMatrix Inc
KQ:109820
Diagnostics & Research 41.52%
Genoray Co. Ltd
KQ:122310
Diagnostics & Research 0.03%
Green Cross Lab Cell Corporation
KQ:144510
Diagnostics & Research 0.18%
Optipharm.CO.LTD
KQ:153710
Diagnostics & Research 20.73%

Annual Asset Resilience Ratio for Bcal Diagnostics Ltd (2021–2022)

The table below shows the annual Asset Resilience Ratio data for Bcal Diagnostics Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 0.00% AU$0.00 AU$8.37 Million --
2021-12-31 37.77% AU$4.00 Million AU$10.59 Million --
pp = percentage points